Theravance Biopharma (NASDAQ:TBPH) Sets New 1-Year High – Time to Buy?

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s share price hit a new 52-week high during trading on Tuesday . The company traded as high as $20.35 and last traded at $20.40, with a volume of 199677 shares traded. The stock had previously closed at $19.65.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on TBPH shares. BTIG Research raised their target price on Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, November 26th. Wall Street Zen lowered Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Oppenheimer initiated coverage on Theravance Biopharma in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price target for the company. HC Wainwright lifted their price objective on Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Finally, Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $27.80.

Theravance Biopharma Price Performance

The business’s fifty day moving average price is $18.17 and its 200-day moving average price is $14.84. The stock has a market capitalization of $1.03 billion, a PE ratio of 35.67 and a beta of 0.14.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.10. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. The company had revenue of $19.99 million during the quarter, compared to analysts’ expectations of $19.89 million. On average, analysts expect that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $18.75, for a total transaction of $582,506.25. Following the completion of the sale, the senior vice president directly owned 277,695 shares in the company, valued at $5,206,781.25. This represents a 10.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Large investors have recently modified their holdings of the business. Quarry LP purchased a new position in Theravance Biopharma in the third quarter worth about $26,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,411 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 781 shares during the last quarter. CIBC Private Wealth Group LLC grew its position in Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares during the period. Finally, AQR Capital Management LLC bought a new stake in Theravance Biopharma during the first quarter valued at approximately $101,000. 99.10% of the stock is owned by institutional investors.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.